Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Haematological cancer

Tabelecleucel is effective in EBV-positive lymphoproliferative disease

Nature Reviews Clinical Oncology volume 21, page 251 (2024)Cite this article

Subjects

Epstein–Barr virus (EBV)-positive lymphoproliferative disease can occur following allogeneic haematopoietic stem-cell transplantation (HSCT) or solid organ transplantation (SOT). Several treatment options, including rituximab, are available for patients with this disease, although relapse occurs in ~50% and is associated with a poor prognosis. Now, the results of the phase III ALLELE trial demonstrate the promising efficacy of tabelecleucel, an ‘off-the-shelf’ polyclonal EBV-specific T cell product from EBV-seropositive donors that is selected for each patient on the basis of a partially matched HLA profile, in this setting.

Patients with EBV-positive lymphoproliferative disease that was relapsed and/or refractory to rituximab after HSCT (n = 14) or to rituximab ± chemotherapy after SOT (n = 29) received three tabelecleucel infusions (2 × 106 cells each). Objective response rate (ORR) in the HSCT and SOT groups separately was the primary end point.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Mahadeo, K. M. et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(23)00649-6 (2024)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Tabelecleucel is effective in EBV-positive lymphoproliferative disease. Nat Rev Clin Oncol 21, 251 (2024). https://doi.org/10.1038/s41571-024-00873-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-024-00873-3

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer